<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35595874</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1590-3478</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title>
          <ISOAbbreviation>Neurol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-06144-2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Episodic ataxia type 2 is an autosomal dominant channelopathy, caused by genetic variants in the voltage-dependent calcium channel a-1 subunit (CACNA1A), which is characterized by intermittent episodes of vertigo and ataxia. A slow progression of cerebellar signs is commonly observed in the course of the disease. Treatment with the carbonic anhydrase inhibitor acetazolamide is recommended.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We report the cases of two patients with EA-2 and migraine, linked to a novel CACNA1A mutation associated with disabling ictal and interictal disease, which did not respond to acetazolamide.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A 30-year-old woman and a 50-year-old man, who was a ski instructor, reported disabling episodes of rotatory vertigo and progressive interictal ataxia. In both cases, the disease progressed despite treatment with acetazolamide. The concomitant use of topiramate and 4-aminopyridine significantly reduced the frequency and severity of relapses and migraine and improved the interictal cerebellar progression in both cases.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We propose combined applications of topiramate and 4-aminopyridine in refractory cases and those with poor tolerance to acetazolamide and also in those with frequent associated migraine. The effectiveness of this combination of drugs for treating intermittent ataxic episodes and interictal signs in EA-2 has not been previously reported.</AbstractText>
          <CopyrightInformation>© 2022. Fondazione Società Italiana di Neurologia.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>González-Mingot</LastName>
            <ForeName>Cristina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Universitat de Lleida, Hospital Universitari Arnau de Vilanova, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain. crismingot@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>López-Ortega</LastName>
            <ForeName>Ricard</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genetics, Universitat de Lleida, Hospital Universitari Arnau de Vilanova, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brieva-Ruiz</LastName>
            <ForeName>Luis</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Universitat de Lleida, Hospital Universitari Arnau de Vilanova, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Italy</Country>
        <MedlineTA>Neurol Sci</MedlineTA>
        <NlmUniqueID>100959175</NlmUniqueID>
        <ISSNLinking>1590-1874</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">4-Aminopyridine</Keyword>
        <Keyword MajorTopicYN="N">CACNA1A mutations</Keyword>
        <Keyword MajorTopicYN="N">Episodic ataxia type 2</Keyword>
        <Keyword MajorTopicYN="N">Ictal symptoms</Keyword>
        <Keyword MajorTopicYN="N">Interictal progression</Keyword>
        <Keyword MajorTopicYN="N">Topiramate</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>23</Hour>
          <Minute>24</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35595874</ArticleId>
        <ArticleId IdType="doi">10.1007/s10072-022-06144-2</ArticleId>
        <ArticleId IdType="pii">10.1007/s10072-022-06144-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Strupp M, Zwergal A, Brandt T (2007) Episodic ataxia type 2. Neurotherapeutics 4:267–273</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nurt.2007.01.014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baloh RW, Yue Q, Furman JM, Nelson SF (1997) Familial episodic ataxia: clinical heterogeneity in four families linked to chromosome 19p. Ann Neurol 41:8–16</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410410105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harno H, Hirvonen T, Kaunisto MA et al (2004) Acetazolamide improves neurological abnormalities in a family with episodic ataxia type 2 (EA-2). J Neurol 251:232</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-004-0299-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zesiewicz TA, Wilmot G, Kuo SH, Perlman S, Greenstein PE, Ying SH, Ashizawa T, Subramony SH, Schmahmann JD, Figueroa KP et al (2018) Comprehensive systematic review summary: treatment of cerebellar motor dysfunction and ataxia: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Neurology 90(10):464–471</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000005055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H, Jang D-H, Jang J-H, Kim T (2017) Effectiveness of levetiracetam in an acetazolamide-unresponsive patient with episodic ataxia type 2 by a novel CACNA1A nonsense mutation. Eur J Neurol 24(7):e43–e44. https://doi.org/10.1111/ene.13327</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.13327</ArticleId>
            <ArticleId IdType="pubmed">28643957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Na S, Kim T (2021) Efficacy of levetiracetam in patients with episodic ataxia type 2 caused by CACNA1A mutation: three case reports. Neurol Sci 42(9):3897–3899. https://doi.org/10.1007/s10072-021-05368-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-021-05368-y</ArticleId>
            <ArticleId IdType="pubmed">34085110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gandini J, Manto M, Bremova-Ertl T, Feil K, Strupp M (2020) The neurological update: therapies for cerebellar ataxias in 2020. J Neurol 267(4):1211–1220. https://doi.org/10.1007/s00415-020-09717-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-020-09717-3</ArticleId>
            <ArticleId IdType="pubmed">32002650</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
